VIRIDIAN THERAPEUTICS INC (VRDN)

Top movers in Friday's after hours session

After hours stock analysis on 2024-11-15: top gainers and losers in today's session.

Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tuesday 10/1 Insider Buying Report: VRDN, ENGN

Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

Notable Tuesday Option Activity: BOOT, VRDN, BYON

Viridian Therapeutics (VRDN) Shares Cross Above 200 DMA

Viridian Spikes On A 'Bull-Case Scenario' For Eye Drug Considered Amgen Rival

The results are also promising for the next-generation version of that drug.

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease

Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VRDN Stock Earnings: Viridian Therapeutics Misses EPS, Misses Revenue for Q2 2024

VRDN stock results show that Viridian Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense

Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.

3 Small-Cap Stocks With Explosive 2X Growth Potential

Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences

Viridian Therapeutics Enters Oversold Territory (VRDN)

Viridian Therapeutics to Participate in Upcoming May Investor Conferences

VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024

VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024

Viridian Therapeutics is Now Oversold (VRDN)